Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CVD 1301.V01 - HangZhou ConVerd

Next Previous
Search
Drug Profile

CVD 1301.V01 - HangZhou ConVerd

Alternative Names: CVD-1301.V01 - HangZhou ConVerd; hV-01; V 01

Latest Information Update: 21 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hangzhou Converd
  • Class Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Malignant melanoma

Most Recent Events

  • 05 Jul 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (Intratumoural)
  • 23 Jun 2023 Hangzhou Converd plans a phase I trial for Solid tumours (Late-stage disease, In adults, In the elderly, Second-line therapy or greater) in China (Intratumoural, Injection) (NCT05914376)
  • 28 May 2023 No recent reports of development identified for preclinical development in Malignant-melanoma in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top